Effects of Rosemary Essential Oil on Human Cognition (Rosmarinus)
28 de abril de 2026 actualizado por: Heloisa de Freitas Pacífico, Federal University of Paraíba
The Use of Rosmarinus Officinalis L. Essential Oil (Camphor and Cineol Chemotypes) in Cognition: a Randomized, Double-blind, Placebo-controlled Study
Aromatherapy is one of the complementary therapies that is carried out through essential oils.
The essential oil of Rosmarinus Officinalis L. (rosemary) has been gaining attention in aromatherapy research, as studies have shown that the use of this oil is one of the promising non-pharmacological therapies for cognition.
In this way, inhalation of rosemary essential oil is one of the forms of cognitive intervention across different age groups.
The study will aim to analyze the effect of rosemary essential oil, with the following chemotypes: camphor and cineole, on the cognitive performance of adults.
Significant differences are expected between the control (placebo) and experimental groups, given that studies in humans have already shown significant effects of rosemary essential oil on cognition.
Considering the inclusion and exclusion criteria of the study, participants will be allocated to either the control or experimental group.
Consequently, the application of the tests will be carried out neuropsychological tests for the pre-test evaluation, followed by aromatherapy (acute phase) and the reapplication of the tests (post-test phase 1).
For 14 days, the participants will chronically use rosemary essential oil and at the end they will participate in the reapplication of the neuropsychological tests (post-test phase 2).
For inferential analyses, the ANOVA test or its non-parametric equivalent will be used.
In addition, linear regressions may be performed to verify how much the essential oil can predict the outcome of the study's dependent variables.
Effect Size will also be calculated.
Keywords: Chronic intervention; neuropsychology; aromatherapy.
Descripción general del estudio
Estado
Activo, no reclutando
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
63
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Paraíba
-
João Pessoa, Paraíba, Brasil, 58062-106
- Helô
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Sí
Descripción
Inclusion Criteria:
- 1a Healthy adults
- 1b should be able to inhale the essential oil
Exclusion Criteria:
- 2a Neurodegenerative diseases
- 2b Traumatic brain injury
- 2c Brain tumors
- 2d Multiple sclerosis
- 2e Epileptic seizures
- 2f Anxiety Disorder
- 2g Depressive Disorders,
- 2h Uncontrolled arterial hypertension,
- 2i nutritional deficiency or thyroid disease.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: essential oil of Rosmarinus officinalis 1
Inhalation of 2 drops of rosemary camphor essential oil for 5 minutes, once a day for 1 week consecutive on a cotton pad followed
|
oil essential
|
|
Sin intervención: Placebo
Inhalation of 2 drops of sunflower essential oil for 5 minutes, once a day for 1 week consecutive on a cotton pad followed
|
|
|
Comparador activo: essential oil of Rosmarinus officinalis 2
Inhalation of 2 drops of rosemary cineol essential oil for 5 minutes, for once a day for 1 week consecutive on a cotton pad followed
|
oil essential
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
STROOP TEST
Periodo de tiempo: Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
Unit of measurement: time (seconds)
|
Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Subteste Digits of the Test WAIS-III - (Wechsler Adult Scale)
Periodo de tiempo: Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1a. Maximum raw score: 30 1b. Minimum raw score: 2 |
Cognitive tests were administered at the following stages: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Subtest Number and Letter Sequence of the WAIS-III Test - (Wechsler Adult Scale)
Periodo de tiempo: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 21 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Tower of London
Periodo de tiempo: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 46 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Token Test
Periodo de tiempo: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 36 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Corsi Blocks
Periodo de tiempo: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 30 1b. Minimum raw score: 0 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
|
Hopkins Verbal Learning
Periodo de tiempo: Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
1.0 Measurement Units: raw score 1a. Maximum raw score: 0 1b. Minimum raw score: 36 |
Cognitive test were administered at the following times: "Before the intervention (baseline), immediately after the intervention, and 1 week after the intervention."
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
1 de marzo de 2025
Finalización primaria (Estimado)
1 de diciembre de 2026
Finalización del estudio (Estimado)
31 de diciembre de 2026
Fechas de registro del estudio
Enviado por primera vez
13 de abril de 2026
Primero enviado que cumplió con los criterios de control de calidad
28 de abril de 2026
Publicado por primera vez (Actual)
1 de mayo de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
1 de mayo de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
28 de abril de 2026
Última verificación
1 de abril de 2026
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 80434324.0.0000.5188
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .